MedTrace Logo

Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents

NCT03445468 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 379

Last updated 2020-05-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the immunogenicity and safety of 'IL-YANG Quadrivalent Seasonal Influenza Vaccine' in healthy Korean children and adolescents.

Conditions

  • Influenza, Human

Interventions

BIOLOGICAL

IL-YANG Quadrivalent Influenza Vaccine

A single 0.5mL dose administrated as an intramuscular injection.

BIOLOGICAL

IL-YANG Flu Vaccine Pre-filled Syringe

A single 0.5mL dose administrated as an intramuscular injection.

Sponsors & Collaborators

  • Il-Yang Pharm. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jin-Han Kang, MD.PhD · The catholic university of Korea, Seoul ST. Marry's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-20
Primary Completion
2017-12-29
Completion
2018-08-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03445468 on ClinicalTrials.gov